CORC

在结果中检索

CORC

浏览/检索结果: 共32条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study 期刊论文
LUNG CANCER, 2019, 卷号: 130
作者:  Wu, Yi-Long;  Zhou, Caicun;  Lu, Shun;  Qin, Shukui;  Pan, Hongming
收藏  |  浏览/下载：23/0  |  提交时间：2019/12/05
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial 期刊论文
LANCET RESPIRATORY MEDICINE, 2018, 卷号: 6, 期号: 11
作者:  Yue, Dongsheng;  Xu, Shidong;  Wang, Qun;  Li, Xiaofei;  Shen, Yi
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05
CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non- small cell lung cancer (EMERGING): A randomised study 会议论文
作者:  Zhong, W-Z.;  Wu, Y-L.;  Chen, K-N.;  Chen, C.;  Gu, C-D.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study 期刊论文
BMC PULMONARY MEDICINE, 2018, 卷号: 18
作者:  Jiang, Ye;  Zhang, Jing;  Huang, Juanjuan;  Xu, Bo;  Li, Ning
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib 会议论文
作者:  Liu, Fatao;  Zhou, Yi;  Zhou, Zhen;  Liu, Yun;  Chen, Zhiwei
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. 会议论文
作者:  Xing, Ligang;  Wu, Gang;  Wang, Lvhua;  Li, Jian-Cheng;  Wang, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients 会议论文
作者:  Yue, D.;  Xu, S.;  Wang, Q.;  Li, X.;  Shen, Y.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer 期刊论文
ONCOTARGET, 2017, 卷号: 8, 期号: 65
作者:  Xia, Jinjing;  Bai, Hao;  Yan, Bo;  Li, Rong;  Shao, Minhua
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment 期刊论文
CLINICAL CANCER RESEARCH, 2017, 卷号: 23, 期号: 17
作者:  Niu, Xiaomin;  Liu, Fatao;  Zhou, Yi;  Zhou, Zhen;  Zhou, Daizhan
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition 期刊论文
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 卷号: 40, 期号: 8
作者:  Lou, Wei;  Chen, Yan;  Zhu, Ke-ying;  Deng, Huizi;  Wu, Tianhao
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace